American journal of epidemiology · 2026
Cardiovascular disease and mortality following placental abruption.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ananth Cande V, Lee Rachel, Valeri Linda, Grandi Sonia M, Rosen Todd, Kostis William J, PACER Study Investigators
Аннотация
We investigate the relationship between placental abruption and cardiovascular disease (CVD) events using a population-based, retrospective cohort study of individuals who delivered a singleton birth between 1993 and 2020 in New Jersey, USA. We fit multistate weighted Cox models to estimate the risks of non-fatal CVD hospitalization, all-cause mortality, and non-fatal CVD hospitalization to all-cause mortality. We examine these associations in two non-overlapping cohorts of individuals with their first delivery only (parity 1) and those with the first two consecutive deliveries (parity 1-2). Associations were corrected for unmeasured confounding bias. Of 2 874 671 deliveries, 1.0% (n = 28 913) had an abruption. The median follow-up was 16 years (range, 0-28 years). Compared to no abruption, placental abruption among first deliveries was associated with adjusted hazard ratio (HR) of 1.27 (95% confidence interval [CI], 1.11-1.46) for the transition from delivery to non-fatal CVD hospitalization; HR, 1.77 (95% CI, 1.28-2.44) for all-cause mortality; and HR, 1.52 (95% CI, 0.98-2.37) for non-fatal CVD hospitalization to all-cause mortality. The corresponding HRs for recurrent placental abruption (parity 1-2 cohort) were stronger, although less precise. Corrections for unmeasured confounding slightly attenuated these risks. These findings underscore the importance of placental abruption as a potential risk factor for maternal CVD risks.